Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹13,283 Cr
Revenue (TTM)
₹7,267 Cr
Net Profit (TTM)
₹629 Cr
ROE
11.6 %
ROCE
13.5 %
P/E Ratio
21.1
P/B Ratio
2.4
Industry P/E
48.01
EV/EBITDA
12.1
Div. Yield
1.6 %
Debt to Equity
0.2
Book Value
₹277.4
EPS
₹33.7
Face value
2
Shares outstanding
196,563,124
CFO
₹6,480.57 Cr
EBITDA
₹9,302.81 Cr
Net Profit
₹6,116.57 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alembic Pharma
| -20.1 | -13.0 | -20.2 | -17.7 | 12.1 | -5.6 | 1.0 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Alembic Pharma
| -19.3 | 39.2 | 32.6 | -28.6 | -23.1 | 87.7 | -2.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alembic Pharma
|
676.3 | 13,282.8 | 7,266.8 | 627.5 | 11.9 | 12.6 | 21.1 | 2.4 |
| 2,257.8 | 18,500.8 | 1,215.1 | 284.8 | 28.7 | 21.1 | 64.5 | 12.2 | |
| 306.3 | 11,719.9 | 2,051.5 | 180.5 | 11.6 | 7.7 | 58.1 | 3.1 | |
| 587.2 | 14,551.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 26.7 | 3.5 | |
| 856.6 | 13,645.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 31.5 | 2.1 | |
| 957.9 | 17,149.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11 | 2.0 | |
| 1,471.6 | 16,867.1 | 1,419.3 | 20.1 | 8.4 | 0.5 | 839.1 | 2.9 | |
| 143.1 | 19,028.2 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 419.9 | 16,903.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 48 | 3.6 | |
| 1,215.6 | 19,800.5 | 3,151.0 | -10.0 | 8.4 | 2.5 | 900 | 4.3 |
5 min read•By Rajan Gulati
Mid caps that are thriving on growth & value
6 min read•By Rajan Gulati
We try to generate 20 per cent returns
2 min read•By Value Research
3 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology,... ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India. Read more
Incorporated
2010
Chairman
Chirayu Amin
Managing Director
Shaunak Amin
Group
Alembic
Headquarters
Vadodara, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Alembic Pharmaceuticals Ltd is ₹676.30 (NSE) and ₹675.75 (BSE) as of 18-Mar-2026 IST. Alembic Pharmaceuticals Ltd has given a return of 12.15% in the last 3 years.
The P/E ratio of Alembic Pharmaceuticals Ltd is 21.12 times as on 18-Mar-2026, a 56 discount to its peers’ median range of 48.01 times.
The P/B ratio of Alembic Pharmaceuticals Ltd is 2.44 times as on 18-Mar-2026, a 21 discount to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
31.31
|
3.52
|
|
2024
|
31.35
|
4.01
|
|
2023
|
28.50
|
2.23
|
|
2022
|
27.97
|
2.78
|
|
2021
|
16.55
|
3.74
|
The 52-week high and low of Alembic Pharmaceuticals Ltd are Rs 1,107.90 and Rs 665.10 as of 19-Mar-2026.
Alembic Pharmaceuticals Ltd has a market capitalisation of ₹ 13,283 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Alembic Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹6.30
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.